share_log

Lucid Gr Analyst Ratings

Benzinga ·  Nov 27, 2023 08:07
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/27/2023 Needham Downgrades Buy → Hold
11/09/2023 -4.42% Morgan Stanley $5 → $4 Maintains Underweight
11/08/2023 19.47% RF Lafferty → $5 Downgrades Buy → Hold
11/08/2023 43.37% Cantor Fitzgerald $10 → $6 Downgrades Overweight → Neutral
11/08/2023 19.47% Needham $9 → $5 Maintains Buy
09/19/2023 43.37% RBC Capital → $6 Reiterates Sector Perform → Sector Perform
09/08/2023 43.37% RBC Capital → $6 Initiates Coverage On → Sector Perform
09/06/2023 67.26% Baird → $7 Initiates Coverage On → Neutral
08/11/2023 19.47% Exane BNP Paribas $6.5 → $5 Downgrades Neutral → Underperform
08/09/2023 79.21% Citigroup $8 → $7.5 Maintains Neutral
08/08/2023 115.05% Needham $10 → $9 Maintains Buy
07/17/2023 91.16% B of A Securities → $8 Reinstates → Neutral
07/13/2023 19.47% Morgan Stanley $5 → $5 Reiterates Underweight → Underweight
07/13/2023 138.95% Cantor Fitzgerald → $10 Reiterates Overweight → Overweight
07/03/2023 91.16% Citigroup → $8 Reinstates → Neutral
05/09/2023 138.95% Cantor Fitzgerald $13 → $10 Maintains Outperform
05/09/2023 138.95% Needham $16 → $10 Maintains Buy
05/09/2023 91.16% B of A Securities $10 → $8 Maintains Neutral
03/02/2023 174.79% Citigroup $12 → $11.5 Maintains Buy
02/23/2023 186.74% RF Lafferty $17 → $12 Maintains Buy
02/23/2023 Exane BNP Paribas Downgrades Outperform → Neutral
02/23/2023 210.63% Cantor Fitzgerald $18 → $13 Maintains Overweight
02/23/2023 138.95% B of A Securities $18 → $10 Downgrades Buy → Neutral
01/25/2023 19.47% Morgan Stanley $10 → $5 Maintains Underweight
12/15/2022 401.79% B of A Securities → $21 Reinstates → Buy
11/30/2022 186.74% Evercore ISI Group → $12 Initiates Coverage On → In-Line
11/10/2022 138.95% Morgan Stanley $12 → $10 Maintains Underweight
09/27/2022 449.58% Cantor Fitzgerald → $23 Initiates Coverage On → Overweight
09/15/2022 569.06% Citigroup → $28 Reinstates → Buy
09/15/2022 Needham Initiates Coverage On → Underperform
09/12/2022 354% RF Lafferty → $19 Initiates Coverage On → Buy
05/09/2022 760.22% Citigroup $45 → $36 Maintains Buy
04/11/2022 Exane BNP Paribas Initiates Coverage On → Outperform
03/03/2022 186.74% Morgan Stanley $16 → $12 Maintains Underweight
01/11/2022 Redburn Partners Initiates Coverage On → Neutral
12/20/2021 Guggenheim Initiates Coverage On → Neutral
09/15/2021 616.85% B of A Securities → $30 Initiates Coverage On → Buy
09/14/2021 186.74% Morgan Stanley → $12 Initiates Coverage On → Underweight
09/09/2021 569.06% Citigroup → $28 Initiates Coverage On → Buy

What is the target price for Lucid Gr (LCID)?

The latest price target for Lucid Gr (NASDAQ: LCID) was reported by Needham on November 27, 2023. The analyst firm set a price target for $0.00 expecting LCID to fall to within 12 months (a possible -100.00% downside). 26 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Lucid Gr (LCID)?

The latest analyst rating for Lucid Gr (NASDAQ: LCID) was provided by Needham, and Lucid Gr downgraded their hold rating.

When is the next analyst rating going to be posted or updated for Lucid Gr (LCID)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lucid Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lucid Gr was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.

Is the Analyst Rating Lucid Gr (LCID) correct?

While ratings are subjective and will change, the latest Lucid Gr (LCID) rating was a downgraded with a price target of $0.00 to $0.00. The current price Lucid Gr (LCID) is trading at is $4.18, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment